	A 11 41 A1 -	A well accepted
	Application No.	Applicant(s)
ALC: CAR LIPE	09/424,840	BERCHTOLD ET AL.
Notice of Allowability	Examiner	Art Unit
	Larry R. Helms	1642
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED or other appropriate comm IGHTS. This application is	in this application. If not included nunication will be mailed in due course. THIS
1. This communication is responsive to the amendment filed	<u>12/16/03</u> .	
2. The allowed claim(s) is/are 30, 33-36, renumbered claims	1-5, respectively.	
3. The drawings filed on are accepted by the Examine		
 4.	nder 35 U.S.C. § 119(a)-(d)	or (f).
 Certified copies of the priority documents have 		
Certified copies of the priority documents have	been received in Applicati	on No
Copies of the certified copies of the priority do	cuments have been receive	ed in this national stage application from the
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
5. Acknowledgment is made of a claim for domestic priority un reference was included in the first sentence of the specification.	ation or in an Application D	ata Sheet. 37 CFR 1.78.
 (a) The translation of the foreign language provisional a 6. Acknowledgment is made of a claim for domestic priority upon the first sentence of the specification or in an Application 	nder 35 U.S.C. §§ 120 and	/or 121 since a specific reference was included
Applicant has THREE MONTHS FROM THE "MAILING DATE" of below. Failure to timely comply will result in ABANDONMENT of		
7. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give		
8. CORRECTED DRAWINGS (as "replacement sheets") mus (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No	son's Patent Drawing Revie	
(b) ☐ including changes required by the proposed drawing c(c) ☐ including changes required by the attached Examiner's		• • •
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t		
9. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT FOR T		
Attachment(s)		
1 ☐ Notice of References Cited (PTO-892)	5 ☐ Notice of In	formal Patent Application (PTO-152)
 2 Notice of Draftperson's Patent Drawing Review (PTO-948) 3 Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No. 	6☐ Interview S	ummary (PTO-413), Paper No
	3), 7⊠ Examiner's	Amendment/Comment
4☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	8∏ Examiner's 9∏ Other	Statement of Reasons for Allowance
	LARRY R. HELN PRIMARY EX	IS, PH.D IMINER

Application/Control Number: 09/424,840

Art Unit: 1642

EXAMINER'S AMENDMENT

Page 2

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ms. Katts on 1/20/04.

The application has been amended as follows:

Claim 31 has been canceled.

Claim 30 has been amended as follows:

In claim 30, line one, the term "thereof" has been added after "antigen binding fragment".

In claim 30, line four, the phrase "or antigen binding fragment" has been added after the phrase "said antibody".

Claim 35 has been replaced with the attached claim 35 below.

1/21/02/ 1/21/02/ 36. (CURRENTLY AMENDED) THE ANTIBODY OR ANTIGEN BINDING FRAGMENT ACCORDING TO CLAIM
36. IN COMBINATION WITH A SECOND HUMAN ANTIBODY OR ANTIGEN BINDING FRAGMENT WHICH
INCLUDES A LIGHT CHAIN, WHEREIN SAID LIGHT CHAIN FURTHER COMPRISING A LIGHT CHAIN OR
ANTIGEN BINDING FRAGMENT THEREOF, WHEREIN SAID ANTIBODY OR ANTIGEN BINDING FRAGMENT
THEREOF IS ABLE TO BIND TO GPIIB/IIIA, AND WHEREIN THE LIGHT CHAIN COMPRISES A CDR3 REGION,
A CDR2 REGION AND A CDR1 REGION, WHEREIN SAID CDR3 REGION IS ENCODED BY A NUCLEOTIDE
SEQUENCE SELECTED FROM THE GROUP CONSISTING OF:

(A) A NUCLEOTIDE SEQUENCE WHICH ENCODES THE AMINO ACID SEQUENCE:

ATWDDGLNGPV(SEQIDNO:37), AND

(B) A NUCLEOTIDE SEQUENCE WHICH ENCODES THE AMINO ACID SEQUENCE

AAWDDSLNGWV(SEQIDNO:38),

AND SAID CDR I REGION IS ENCODED BY A NUCLEOTIDE SEQUENCE SELECTED FROM THE GROUP CONSISTING OF:

(C) A NUCLEOTIDE SEQUENCE WHICH ENCODES THE AMINO ACID SEQUENCE:

SGSSSNIRSNPVS(SEQIDNO: 39), AND

(D) A NUCLEOTIDE SEQUENCE WHICH ENCODES THE AMINO ACID SEQUENCE:

SGSSSNIGSNTVN (SEQ ID NO: 40),

AND SAID CDR2 REGION IS ENCODED BY A NUCLEOTIDE SEQUENCE SELECTED FROM THE GROUP CONSISTING OF:

(E) A NUCLEOTIDE SEQUENCE WHICH ENCODES THE AMINO ACID SEQUENCE:

GSHQRPS (SEQID NO: 41), AND

(F) A NUCLEOTIDE SEQUENCE WHICH ENCODES THE AMINO ACID SEQUENCE:

SNNQRPS (SEQID NO: 42).

Application/Control Number: 09/424,840

Art Unit: 1642

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Larry R. Helms, Ph.D, whose telephone number is (703) 306-5879.

LARRY R. HELAS, PH.D. DRIMARY EXAMINER

*	
	*
	(C)
	-
	and the second